AIXC · AIxCrypto Holdings, Inc.

Shares underlying the stock option vest over three years in equal annual installments from the date of grant.

Shares underlying the stock option vest over three years in equal annual installments from the date of grant.

Shares underlying the stock option vest over three years in equal annual installments from the date of grant.

Shares underlying the stock option vest over three years in equal annual installments from the date of grant.

Shares underlying the stock option vest over three years in equal annual installments from the date of grant.

Shares underlying the stock option vest over three years in equal annual installments from the date of grant.

Shares underlying the stock option vest over three years in equal annual installments from the date of grant.

Shares underlying the stock option vest over three years in equal annual installments from the date of grant.

Shares underlying the stock option vest over three years in equal annual installments from the date of grant.

Shares underlying the stock option vest over three years in equal annual installments from the date of grant.

Shares underlying the stock option vest over three years in equal annual installments from the date of grant.

Shares underlying the stock option vest over three years in three equal annual installments from the date of grant.

Shares underlying the stock option vest over two-plus years in three equal annual installments from the vesting commencement date of May 17, 2021.

Shares underlying the stock option vest over three years in three equal annual installments from the date of grant.

Shares underlying the stock option vest over three years in equal annual installments from the date of grant.

Shares underlying the stock option vest over three years in equal annual installments from the date of grant.

Shares underlying the stock option vest over three years in equal annual installments from the date of grant.

Shares underlying the stock option vest over three years in equal annual installments from the date of grant.

Shares underlying the stock option vest over three years in equal annual installments from the date of grant.

Shares underlying the stock option vest over three years in equal annual installments from the date of grant.

Shares underlying the stock option vest over three years in equal annual installments from the date of grant.

Shares underlying the stock option vest over three years in equal annual installments from the date of grant.

Shares underlying the stock option vest over three years in equal annual installments from the date of grant.

Shares underlying the stock option vest over three years in equal annual installments from the date of grant.

Shares underlying the stock option vest over three years in equal annual installments from the date of grant.

Pursuant to the Merger, Qualigen Series C convertible preferred stock warrants previously held by the Reporting Person were assumed by the Issuer and may be exercised solely for shares of common stock of the Issuer.

Pursuant to the Merger, Qualigen Series C convertible preferred stock warrants previously held by the Reporting Person were assumed by the Issuer and may be exercised solely for shares of common stock of the Issuer.

Pursuant to the Merger, Qualigen Series C convertible preferred stock warrants previously held by the Reporting Person were assumed by the Issuer and may be exercised solely for shares of common stock of the Issuer.

On May 22, 2020, a reverse merger transaction between the Issuer and Qualigen, Inc. ("Qualigen") was consummated such that Qualigen became a wholly-owned subsidiary of the Issuer (the "Merger"). Pursuant to and effective as of the closing of the Merger (the "Closing"), the Reporting Person became an officer of the Issuer.

Immediately prior to the Closing, the Reporting Person was a stockholder of Qualigen. Pursuant to the Merger, the shares of Qualigen common stock previously held by the Reporting Person were converted into 9,841 shares of common stock of the Issuer.

On May 22, 2020, a reverse merger transaction between the Issuer and Qualigen, Inc. ("Qualigen") was consummated such that Qualigen became a wholly-owned subsidiary of the Issuer (the "Merger"). Pursuant to and effective as of the closing of the Merger (the "Closing"), the Reporting Person became an officer of the Issuer.

Immediately prior to the Closing, the Reporting Person held Qualigen Series C convertible preferred stock warrants. Pursuant to the Merger, the Qualigen Series C convertible preferred stock warrants previously held by the Reporting Person were assumed by the Issuer and may be exercised solely for shares of common stock of the Issuer.

Pursuant to the Merger, Qualigen Series C convertible preferred stock warrants previously held by the Reporting Person were assumed by the Issuer and may be exercised solely for shares of common stock of the Issuer.

On May 22, 2020, a reverse merger transaction between the Issuer and Qualigen, Inc. ("Qualigen") was consummated such that Qualigen became a wholly-owned subsidiary of the Issuer (the "Merger"). Pursuant to and effective as of the closing of the Merger (the "Closing"), the Reporting Person became a director of the Issuer.

Immediately prior to the Closing, the Reporting Person held Qualigen Series C convertible preferred stock warrants. Pursuant to the Merger, the Qualigen Series C convertible preferred stock warrants previously held by the Reporting Person were assumed by the Issuer and may be exercised solely for shares of common stock of the Issuer.

On May 22, 2020, a reverse merger transaction between the Issuer and Qualigen, Inc. ("Qualigen") was consummated such that Qualigen became a wholly-owned subsidiary of the Issuer (the "Merger"). Pursuant to and effective as of the closing of the Merger (the "Closing"), the Reporting Person became an officer of the Issuer.

Immediately prior to the Closing, the Reporting Person held Qualigen Series C convertible preferred stock warrants. Pursuant to the Merger, the Qualigen Series C convertible preferred stock warrants previously held by the Reporting Person were assumed by the Issuer and may be exercised solely for shares of common stock of the Issuer.

Pursuant to the Merger, Qualigen Series C convertible preferred stock warrants previously held by the Reporting Person were assumed by the Issuer and may be exercised solely for shares of common stock of the Issuer.

On May 22, 2020, a reverse merger transaction between the Issuer and Qualigen, Inc. ("Qualigen") was consummated such that Qualigen became a wholly-owned subsidiary of the Issuer (the "Merger"). Pursuant to and effective as of the closing of the Merger (the "Closing"), the Reporting Person became an officer of the Issuer.

Immediately prior to the Closing, the Reporting Person held Qualigen Series C convertible preferred stock warrants. Pursuant to the Merger, the Qualigen Series C convertible preferred stock warrants previously held by the Reporting Person were assumed by the Issuer and may be exercised solely for shares of common stock of the Issuer.

Pursuant to the Merger, Qualigen Series C convertible preferred stock warrants previously held by the Reporting Person were assumed by the Issuer and may be exercised solely for shares of common stock of the Issuer.

Pursuant to the Merger, Qualigen Series C convertible preferred stock warrants previously held by the Reporting Person were assumed by the Issuer and may be exercised solely for shares of common stock of the Issuer.

On May 22, 2020, a reverse merger transaction between the Issuer and Qualigen, Inc. ("Qualigen") was consummated such that Qualigen became a wholly-owned subsidiary of the Issuer (the "Merger"). Pursuant to and effective as of the closing of the Merger (the "Closing"), the Reporting Person became a director of the Issuer.

Immediately prior to the Closing, the Reporting Person held Qualigen Series C convertible preferred stock warrants. Pursuant to the Merger, the Qualigen Series C convertible preferred stock warrants previously held by the Reporting Person were assumed by the Issuer and may be exercised solely for shares of common stock of the Issuer.

On May 22, 2020, a reverse merger transaction between the Issuer and Qualigen, Inc. ("Qualigen") was consummated such that Qualigen became a wholly-owned subsidiary of the Issuer (the "Merger"). Pursuant to and effective as of the closing of the Merger (the "Closing"), the Reporting Person became an officer of the Issuer.

Immediately prior to the Closing, the Reporting Person held Qualigen Series C convertible preferred stock warrants. Pursuant to the Merger, the Qualigen Series C convertible preferred stock warrants previously held by the Reporting Person were assumed by the Issuer and may be exercised solely for shares of common stock of the Issuer.

On May 22, 2020, a reverse merger transaction between the Issuer and Qualigen, Inc. ("Qualigen") was consummated such that Qualigen became a wholly-owned subsidiary of the Issuer (the "Merger"). Pursuant to and effective as of the closing of the Merger (the "Closing"), the Reporting Person became an officer and director of the Issuer.

Immediately prior to the Closing, the Reporting Person was a stockholder of Qualigen. Pursuant to the Merger, the shares of Qualigen common stock previously held by the Reporting Person were converted into 169,192 shares of common stock of the Issuer.